NCT06731530

Brief Summary

The purpose of this study is to assess the effect of pseudoexfoliation syndrome on corneal biomechanics, optical clarity of the cornea, and anterior segment structural features.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
86

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Dec 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 19, 2024

Completed
23 days until next milestone

First Posted

Study publicly available on registry

December 12, 2024

Completed
1 day until next milestone

Study Start

First participant enrolled

December 13, 2024

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2025

Completed
Last Updated

December 27, 2024

Status Verified

December 1, 2024

Enrollment Period

5 months

First QC Date

November 19, 2024

Last Update Submit

December 24, 2024

Conditions

Keywords

pseudoexfoliation syndromebiomechanical parameterscorneal transparency

Outcome Measures

Primary Outcomes (2)

  • Corneal optical density assessed by backscatter measurement

    Corneal optical density assessed by backscatter measurement (COD, corneal optical density) using Pentacam AXL (Oculus, Wetzlar, Germany)

    Baseline, during examination : approx. 1 hour

  • Corneal optical density assessed by forward-scatter measurement

    Corneal optical density assessed by forward-scatter measurement (OSI, objective scatter index) using HD Analyzer (Visiometrics, Terassa, Spain, Keeler)

    Baseline, during examination : approx. 1 hour

Secondary Outcomes (6)

  • Corneal biomechanics using Corvis Scheimpflug Technology

    Baseline, during examination : approx. 1 hour

  • Optical quality measured by HD-analyzer : Strehl ratio

    Baseline, during examination : approx. 1 hour

  • Optical quality measured by HD-analyzer : MTF cut-off

    Baseline, during examination : approx. 1 hour

  • Corneal biomechanics using Corvis Scheimpflug Technology : velocity

    Baseline, during examination : approx. 1 hour

  • Corneal biomechanics using Corvis Scheimpflug Technology : length

    Baseline, during examination : approx. 1 hour

  • +1 more secondary outcomes

Other Outcomes (8)

  • The level of agreement between the two optical density indicators (OSI, COD) after standardization

    Baseline, during examination : approx. 1 hour

  • Anterior chamber depth (mm)

    Baseline, during examination : approx. 1 hour

  • Endothelial cell density (cells/mm2)

    Baseline, during examination : approx. 1 hour

  • +5 more other outcomes

Study Arms (2)

PEX group (patients WITH pseudoexfoliation syndrome)

right or left eye of pseudophakic patients diagnosted with PEX syndrome pre-operatively (PEX positive, as recorded in the pre-operative medical file)

Device: Pentacam-AXLDevice: HD AnalyzerDevice: Corvis STDevice: OCT-A AngiovueDevice: IOLMaster V.5.4Device: Topcon SP-1POther: BCVA (ETDRS), Slit lamp examination, Goldmann Applanation Tonometry, Fundus examination

Control group (patients WITHOUT pseudoexfoliation syndrome)

right or left eye of pseudophakic patients without a pre-operative diagnosis of pseudoexfoliation syndrome (PEX negative, as recorded in the pre-operative medical file)

Device: Pentacam-AXLDevice: HD AnalyzerDevice: Corvis STDevice: OCT-A AngiovueDevice: IOLMaster V.5.4Device: Topcon SP-1POther: BCVA (ETDRS), Slit lamp examination, Goldmann Applanation Tonometry, Fundus examination

Interventions

Pentacam-AXL (Oculus, Wetzlar, Germany)

Control group (patients WITHOUT pseudoexfoliation syndrome)PEX group (patients WITH pseudoexfoliation syndrome)

HD Analyzer (Visiometrics, Terassa, Spain, Keeler)

Control group (patients WITHOUT pseudoexfoliation syndrome)PEX group (patients WITH pseudoexfoliation syndrome)
Corvis STDEVICE

Corvis ST (Oculus, Germany)

Control group (patients WITHOUT pseudoexfoliation syndrome)PEX group (patients WITH pseudoexfoliation syndrome)

OCT-A Angiovue (Optovue, Inc., Fremont, California, USA)

Control group (patients WITHOUT pseudoexfoliation syndrome)PEX group (patients WITH pseudoexfoliation syndrome)

IOLMaster V.5.4 (Carl Zeiss., Meditec)

Control group (patients WITHOUT pseudoexfoliation syndrome)PEX group (patients WITH pseudoexfoliation syndrome)

Topcon SP-1P (Topcon Medical Inc., Tokyo, Japan)

Control group (patients WITHOUT pseudoexfoliation syndrome)PEX group (patients WITH pseudoexfoliation syndrome)

BCVA (ETDRS), Slit lamp examination, Goldmann Applanation Tonometry, Fundus Examination

Control group (patients WITHOUT pseudoexfoliation syndrome)PEX group (patients WITH pseudoexfoliation syndrome)

Eligibility Criteria

Age60 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Participants will be selected from patients who consult at the outpatient clinic of the 2nd Department of Ophthalmology, General Hospital Papageorgiou, Thessaloniki, Greece.

You may qualify if:

  • age 60-80 years.
  • unilateral or bilateral pseudophakia (cataract surgery undergone at Papageorgiou General Hospital, Thessaloniki, Greece).
  • open anterior chamber angle (grade \> 2, van Herick method).

You may not qualify if:

  • History of intraocular surgery other than uncomplicated cataract surgery (phakoemulsification).
  • Cataract surgery within the last 3 months.
  • History of ocular trauma.
  • Use of contact lenses.
  • Corneal pathology.
  • Use of anti-VEGF medications.
  • History of uveitis or active uveitis.
  • Hypertension (IOP \> 21 mmHg) or glaucoma.
  • Myopia or hyperopia greater than 3 diopters.
  • Astigmatism greater than 1.5 diopters.
  • Posterior capsular opacification grade 2, 3, or 4 based on the EPCO grading scale.
  • Tear break-up time \<10 sec

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

2nd Department of Ophthalmology, Papageorgiou General Hospital

Thessaloniki, 56429, Greece

RECRUITING

MeSH Terms

Conditions

Exfoliation Syndrome

Interventions

Slit Lamp

Condition Hierarchy (Ancestors)

Iris DiseasesUveal DiseasesEye Diseases

Intervention Hierarchy (Ancestors)

OphthalmoscopesDiagnostic EquipmentEquipment and Supplies

Study Officials

  • Nikolaos Ziakas, Professor

    Aristotle University Of Thessaloniki

    STUDY CHAIR

Central Study Contacts

Paraskevi Petridou, MD, MSc

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Ophthalmology

Study Record Dates

First Submitted

November 19, 2024

First Posted

December 12, 2024

Study Start

December 13, 2024

Primary Completion

May 1, 2025

Study Completion

May 1, 2025

Last Updated

December 27, 2024

Record last verified: 2024-12

Data Sharing

IPD Sharing
Will share

Deidentified Individual Participant Data (IPD) that underline published results, along with related data dictionaries, will be available only to researchers who will provide a methodologically sound proposal, after acceptance of the proposed protocol by our Institution's IRB. Data requestors will need to sign a data access agreement. The study protocol and statistical analysis plan will also be available, if needed.

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
Data requests can be submitted starting 9 months after article publication and the data will be made accessible for up to 24 months.
Access Criteria
Available only to researchers who will provide a methodologically sound proposal, after acceptance of the proposed protocol by our Institution's IRB. Data requestors will need to sign a data access agreement.

Locations